LLY

1,147.78

-0.89%↓

JNJ

237.21

+2.66%↑

ABBV

225.83

+1.53%↑

UNH

411.66

+1.86%↑

MRK

119.88

+0.93%↑

LLY

1,147.78

-0.89%↓

JNJ

237.21

+2.66%↑

ABBV

225.83

+1.53%↑

UNH

411.66

+1.86%↑

MRK

119.88

+0.93%↑

LLY

1,147.78

-0.89%↓

JNJ

237.21

+2.66%↑

ABBV

225.83

+1.53%↑

UNH

411.66

+1.86%↑

MRK

119.88

+0.93%↑

LLY

1,147.78

-0.89%↓

JNJ

237.21

+2.66%↑

ABBV

225.83

+1.53%↑

UNH

411.66

+1.86%↑

MRK

119.88

+0.93%↑

LLY

1,147.78

-0.89%↓

JNJ

237.21

+2.66%↑

ABBV

225.83

+1.53%↑

UNH

411.66

+1.86%↑

MRK

119.88

+0.93%↑

Accueil・Liste d'Actions・Beam Therapeutics Inc

Beam Therapeutics Inc

Ouvert

SecteurSoins de santé

29.44 -0.44

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

28.87

Max

31.13

Chiffres clés
By Trading Economics
Revenu	-339M -94M
Ventes	-82M 32M
BPA	-0.91
Marge bénéficiaire	-297.177
Employés	522
EBITDA	-362M -102M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+75.44% upside

Dividendes
By Dow Jones
Prochains Résultats	4 août 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	-101M 3B
Ouverture précédente	29.88
Clôture précédente	29.44

Sentiment de l'Actualité

By Acuity

68%

32%

298 / 344 Classement par Healthcare

Beam Therapeutics Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

8 juin 2026, 22:20 UTC

Acquisitions, Fusions, Rachats

Salesforce to Buy m3ter in Nod Toward AI-Native Business Models

8 juin 2026, 15:41 UTC

Principaux Mouvements du Marché

American Battery Shares Jump on Energy Department Victory

8 juin 2026, 23:46 UTC

Market Talk

Nikkei May Rebound After Monday's Selloff -- Market Talk

8 juin 2026, 23:37 UTC

Market Talk

Oil Edges Higher Amid Ongoing Supply Disruption Concerns -- Market Talk

8 juin 2026, 23:25 UTC

Market Talk

Should Australia Consider State-Linked Commodities Export Desk? -- Market Talk

8 juin 2026, 23:25 UTC

Market Talk

Global Equities Roundup: Market Talk

8 juin 2026, 21:57 UTC

Acquisitions, Fusions, Rachats

Salesforce Expects to Close Deal in 2Q of Fiscal 2027

8 juin 2026, 21:56 UTC

Acquisitions, Fusions, Rachats

Salesforce Agrees to Buy m3ter

8 juin 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

8 juin 2026, 19:22 UTC

Market Talk

Oil Settles Higher as Israel-Iran Exchanges Raise Tension -- Market Talk

8 juin 2026, 19:01 UTC

Market Talk

U.S. Natural Gas Futures Pull Back on Weather Outlook -- Market Talk

8 juin 2026, 18:52 UTC

Market Talk

Global Energy Roundup: Market Talk

8 juin 2026, 18:52 UTC

Market Talk

CAD Needs Trade Deal to Trigger Sustained Rally -- Market Talk

8 juin 2026, 18:17 UTC

Market Talk

Oil Pulls Back Further As Iran, Israel Put Strikes on Hold -- Market Talk

8 juin 2026, 17:32 UTC

Market Talk

Bank of Canada Should Incorporate Unemployment Rate Into Its Forecast -- Market Talk

8 juin 2026, 17:29 UTC

Market Talk

Crypto Market Still Stays in 'Extreme Fear' Amid Rebound -- Market Talk

8 juin 2026, 17:29 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

8 juin 2026, 16:55 UTC

Acquisitions, Fusions, Rachats

Monte dei Paschi: Mediobanca Integration Proceeding According to Plan

8 juin 2026, 16:54 UTC

Acquisitions, Fusions, Rachats

Monte dei Paschi to Review Proposals From Banco BPM, Intesa Sanpaolo

8 juin 2026, 16:40 UTC

Market Talk

Cryptocurrencies Rise After Iran and Israel Halt Exchanges of Fire -- Market Talk

8 juin 2026, 16:31 UTC

Market Talk

No Recession in Canada, Scotiabank's CEO Says -- Market Talk

8 juin 2026, 16:27 UTC

Market Talk

Mexican Inflation Seen Easing in May -- Market Talk

8 juin 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

8 juin 2026, 16:03 UTC

Acquisitions, Fusions, Rachats

Orange Bought Stake From Lorca

8 juin 2026, 16:01 UTC

Acquisitions, Fusions, Rachats

Orange Completes Acquisition of Remaining 50% Stake in MasOrange

8 juin 2026, 16:01 UTC

Acquisitions, Fusions, Rachats

Orange Acquires 100% Ownership of MasOrange

8 juin 2026, 15:58 UTC

Market Talk

Global Equities Roundup: Market Talk

8 juin 2026, 15:58 UTC

Market Talk

Gold Trims Losses After Israel, Iran Halt Exchanges of Fire -- Market Talk

8 juin 2026, 15:55 UTC

Market Talk

Markets Price Small Chance USMCA Will Be Dismantled -- Market Talk

8 juin 2026, 15:41 UTC

Market Talk

Gold Falls Below 200-Day Moving Average -- Market Talk

Comparaison

Variation de prix

Beam Therapeutics Inc prévision

Objectif de Prix

By TipRanks

75.44% hausse

Prévisions sur 12 Mois

Moyen 51.58 USD 75.44%

Haut 80 USD

Bas 26 USD

Basé sur 13 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

13 ratings

Achat

Maintien

Vente

Basé sur 13 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Sentiment

By Acuity

298 / 344Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Beam Therapeutics Inc

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.